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Abstract
Background: As many patients who receive antimalarial drugs for treatment of noninfectious,
inflammatory diseases are also immunosuppressed and might have a concomitant bacterial
infection, we studied the effectiveness of these drugs against bacterial infections, to find out
whether they could protect against (and even treat) such conditions and obviate the need for an
additional antibiotic drug.
Methods: Effect of QS on bacterial growth: Escherichia coli (E. coli) HB101 pRI203 were cultured
overnight at 37C in TSB and inoculated (approx 1  107 cells /ml) in MEM in the presence of QS
at various concentrations (0, 50 and 100 M).
The effect of QS at concentration of 50 and 100 M on the entry process of E. coli HB101 pRI203
into HeLa cells was studied under different experimental conditions: 1. QS was incubated with 3 
105 HeLa cells for 60 min at 37C prior to infection. 2. QS was added to HeLa cell monolayers
during the infection period.
Results: QS showed no antibacterial activity after 24 h of incubation.
The invasive efficiency of the bacteria was significantly inhibited at a dose-dependent manner, when
QS was added to HeLa cells for 60 min at 37C prior to infection (condition 1), and to a lesser
extent when added during the period of infection (condition 2).
Conclusions: Although the antimalarials are generally regarded as being inactive against most
extracellular bacterial species, our results indicate that QS significantly inhibited the internalization/
invasion efficacy of E. coli in the host cells.
Background
Antimalarial drugs were first discovered in the seven-
teenth century [1], two and one-half centuries before the
causative agent of malaria was identified. As no other drug
before it, quinine, the first antimalarial agent derived
from the cinchona tree, helped to shape today's world by
enabling explorers and colonists from Europe to survive
in tropical countries and to build their colonial empires
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despite lethal tropical malaria. When physicians were
asked to choose the ten most important drugs being used
in medicine in 1945, quinine and quinacrine were preced-
ed only by penicillin, sulfonamides and blood derivatives
[2]. The antimalarial activity of quinoline antimalarial
drugs can be attributed to the interfering with hemoglob-
in digestion in the blood stages of the malaria parasite's
life cycle. The parasite degrades the host hemoglobin, in
an acidic food vacuole, to generate amino acids for its
own protein synthesis, and producing free heme and reac-
tive oxygen species as toxic by-products. The heme moie-
ties are neutralized by polymerization, and this process is
thought to be the biochemical target for antimalarial
drugs. Although antimalarial drugs were developed pri-
marily to treat malaria, and never lost their place in treat-
ing this life-threatening disease (still a major cause of
infant death in the tropics [3]), they are also beneficial for
many dermatological, immunological, and rheumatolog-
ical diseases, for which they are mostly used today in the
Western world [4].
Some of the many patients who receive antimalarials for
the treatment of non-infective inflammatory diseases (lu-
pus erythematosus and other collagen vascular diseases,
vasculitis, panniculitis, rheumatoid arthritis and others)
are also immunosuppressed because of their disease and/
or treatments and have a concomitant bacterial infection.
These patients often need systemic antibiotics, either as
prophylaxis or for the treatment of active infections of the
skin or other organs.
Therefore, if antimalarials could prove to be effective
against bacterial infections, they can protect against (and
even treat) such conditions and obviate the need for an
additional antibiotic drug.
To examine this possibility, we studied the effect of qui-
nine sulfate (QS) on bacterial growth and on bacterial in-
vasion of cultured cells.
Methods
Organism and media
Escherichia coli (E. coli) HB101 (pRI203) was kindly pro-
vided by Dr. Falkow (Stanford Medical School, Calif.
USA). The pRI203 plasmid carries a chromosomal DNA
fragment of Y. pseudotuberculosis which converts the E. coli
HB101 strain into an organism capable of invading cul-
tured animal cells [5].
E. coli HB101 pRI203 were routinely cultured on trypti-
case soy broth (TSB; BBL, Becton Dickinson Microbiology
Systems, Cockeysville, MD, USA). Ampicillin was added
to the culture media at a final concentration of 50 g/ml
to select the maintenance of the recombinant invasive
plasmid in all the experimental conditions.
Cells
HeLa S3 cells (epithelioid carcinoma of human cervix)
were cultured in Minimum Essential Medium (MEM; Ser-
omed) supplemented with 1.2 g/l NaHCO3, 2 mM
glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin
and 10% heat-inactivated fetal calf serum (FCS), in a 5%
CO2 incubator.
HeLa S3 cells were grown as monolayers at 37C on 12-
well tissue culture clusters (Costar) as described elsewhere
[6].
Chemicals
Quinine sulfate (QS, M.W. 783 kDa) was dissolved in an
ethanol-water ratio of 1:1.
Toxicity of QS towards cultured cells
Cells propagated in tissue-culture clusters were incubated
with different concentration of QS (0, 50 and 100 M) at
37C for 2 h in MEM. The cell monolayers were then
washed with phosphate-buffered saline (PBS); fresh me-
dium was added and the cells were observed and stained
after a 24 h incubation period at 37C.
Effect of QS on bacterial growth
E. coli HB101 pRI203 were cultured overnight at 37C in
TSB and inoculated (approx 1  107 cells /ml) in MEM in
the presence of QS at various concentrations (0, 50 and
100 M). The determination of viable bacteria was per-
formed after 24 h of contact by counting the colony-form-
ing units (CFU) on trypticase soy agar (TSB, BBL).
Invasion assay
Invasion of cultured cells was assayed by a modification of
the technique of Isberg and Falkow (1985) [7]. Briefly,
semiconfluent monolayers of HeLa cells grown without
antibiotics in 12-well plates were infected with bacterial
suspensions (100 bacteria per cell) in the early exponen-
tial phase, corresponding to a subculture of 120 min at
37C. Infection was performed for 1 h at 37C. The cells
were then thoroughly washed with PBS, and 1 ml of fresh
medium containing 100 g/ml gentamicin was added to
each well. After a further 2-h incubation period at 37C,
infected cells were treated with trypsin-EDTA (mixture of
0.05 % trypsin [1/250] and 0.02 % EDTA) for 5 min at
37C and lysed by the addition of 0.1 %Triton-X100. Cell
lysates were diluted in PBS and plated on TSB to quantify
the number of viable intra-cellular bacteria. The invasion
was controlled by the microscopic observation of Giemsa-
stained slides in all experiments.
Invasion assay in presence of QS
The effect of QS at concentration of 50 and 100 M on the
entry process of E. coli HB101 pRI203 into HeLa cells was
studied under different experimental conditions:Annals of Clinical Microbiology and Antimicrobials 2002, 1 http://www.ann-clinmicrob.com/content/1/1/5
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1) QS was incubated with 3  105 HeLa cells for 60 min at
37C prior to infection; cell monolayers were then washed
three times with PBS to remove the QS.
2) QS was added to HeLa cell monolayers during the in-
fection period.
The invasive efficiency was expressed as the number of vi-
able internalized bacteria by counting the CFU.
Results
The initial test of the toxicity of QS toward cultured cells
indicated that after the incubation at 37C for 2-h, QS at
concentrations of 0, 50 and 100 M, produce no damage
to the HeLa cells.
To assay the viability of the microbial cells during the in-
vasion experiments, different concentrations of QS 50 and
100 M, were added to E. coli suspensions (1  107 CFU/
ml) in MEM following an overnight culture at 37C. QS
showed no antibacterial activity after 24 h of incubation.
Effect of QS on E. coli HB 101 pRI203 invasion into cul-
tured cells
HeLa confluent monolayers were infected with bacterial
suspension in a logarithmic-phase growth for 60 min at
37C in the presence and absence of 50 and 100 M of
QS. Extracellular bacteria were killed by the addition of
gentamicin, and the intracellular bacterial CFU were
counted on TSB after lysis of the infected monolayers. Ta-
ble 1I displays the internalization of E. coli in the host
cells, and is expressed as the percent of the inoculated col-
ony-forming units which were internalized. The invasive
efficiency of the bacteria was significantly inhibited, in a
dose-dependent effect, by QS, when the drug was added
for 60 min at 37C prior to infection (condition 1). When
the QS was added to HeLa cell monolayers during the in-
fection period (condition 2), the invasive efficiency of the
bacteria was also reduced but to a lesser degree than in the
first condition.
Discussion
The antimalarials have recently been reported to be en-
dowed with anti-HIV-1 activity and, therefore, proposed
as additional therapy for HIV infection [8–12]. Their place
in the treatment of autoimmune dermatological and
rheumatological diseases has already been widely dis-
cussed in the literature 4. Apart from their well-document-
ed advantages, i.e., excellent bioavailability, low toxicity,
long-term safety, and low-cost, one more property of
these drugs might be of special interest in the setting of
HIV infection and of autoimmune diseases, namely, their
ability to prevent/treat several infectious diseases other
than malaria. The antimalarials have been proven as being
beneficial for several intracellular pathogens, but only in-
tracellular ones that mainly affect individuals with im-
paired cell-mediated immunity, such as Legionella
pneumophila, Histoplasma capsulatum, Francisella tula-
rensis, Penicillium marneffei Cryptococcus neoformans,
Bacillus subtilis, Mycobacterium avium, Mycobacterium
tuberculosis, Toxoplasma gondii [13–20] and others.
Although the antimalarials are generally regarded as being
inactive against most extracellular bacterial species, in the
early seventies one British group reported that the growth
of E. coli could be inhibited by chloroquine [21–24]. An-
other group found that antimalarials inhibited in vitro the
activity of DNA polymerase and RNA polymerase of E. co-
li[25], thus confirming findings of earlier experiments by
others [26,27].
The adhesion of E. coli to host epithelial cells is the very
first step of infections, followed by the internalization of
some bacteria into the cells. The internalization of at-
tached bacteria is a kind of endocytosis rather than an in-
vasion and is thus influenced by the adherence of bacteria
to the epithelial cells. According to Straube et al. chloro-
quine leads to a significant inhibition of internalization of
bacteria by inhibiting endocytosis [28].
In contrast to previous findings [21–24] by Wiseman's
group (which were carried out on chloroquine and not
quinine), our QS experiments failed to show any antibac-
terial activity or any effect on bacterial growth what-so-ev-
er.
Our in vitro invasion assays, however, did show that QS
significantly inhibited the internalization/invasion effica-
cy of E. coli in the host cells, in accordance with one previ-
ous study [28].
Table 1: Invasion efficiency of E. coli HB101 pRI203 into HeLa cells 
in the presence of quinine sulfate (QS)
QS condition 1 condition 2
0 2.95 2.95
50 M 0.64 1.07
100 M 0.46 1.18
Inoculated and internalized viable bacteria were evaluated by counting 
them on agar plates. Invasive efficiency is the percent of the inoculated 
colony-forming units (CFU) which were internalized. Condition 1: QS 
was incubated with 3  105 HeLa cells for 60 min at 37C prior to 
infection; condition 2: QS was added to the HeLa cell monolayers 
during the infection period.Annals of Clinical Microbiology and Antimicrobials 2002, 1 http://www.ann-clinmicrob.com/content/1/1/5
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Conclusions
Our data further support the finding that QS interferes
with invasion and internalization of E. coli into host cells,
thus protecting living cells from its pathogenic effects. In
contrast to the results of previous reports, we demonstrat-
ed that it does not affect bacterial growth.
Apart from the theoretical considerations of these find-
ings in providing further insight into the pathomecha-
nism of bacterial invasion and the contra-action of
antimalarial drugs, our current findings might also have
practical implications in illuminating the antibacterial ac-
tion of antimalarial drugs, data which might be especially
important to immunosuppressed patients who receive
these drugs for autoimmune collagen vascular diseases, or
as additional therapy for AIDS. It is worth noting that the
antimalarials do not act directly on the invading patho-
gens, but rather on the host cells and, therefore, the poten-
tial for microorganisms to become resistant to its effects
may be limited.
The antibacterial action of antimalarials against various
other common bacteria is currently under investigation by
our group.
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